Moderna: $18.4 Billion Cult-Shot Sales in '22, and Other Tales
Moderna is a welfare-queen company. See how your tax dollars are being spent to make them even more frightening in the years to come.
Flipping through Moderna's press release section weaves a frightening story. Keep in mind that all of the press releases collected below are from 2023. I haven’t even touched 2022 yet.
Prepare yourself in case you need to vomit.
Also, keep in mind — the multi-million dollar spending-spree / acquisition spree / abject heist you’ll read about below is largely funded by your tax dollars because ultra-massive government contracts are funding Moderna. Who else buys a product from Moderna? Did they have any revenue in 2019? You can read more about this very timely phenomenon in Whitney Webb’s piece about how Moderna was saved by the Covidpocalypse.
COVID-19: Moderna Gets Its Miracle
COVID-19 erased the regulatory and trial-related hurdles that Moderna could never surmount before. Yet, how did Moderna know that COVID-19 would create those conditions months before anyone else, and why did they later claim that their vaccine being tested in NIH trials was different than their commercial candidate?
The Mystery Injections aren’t free — you’re paying for them with your tax dollars — along with some printed Zimbabwean US dollars conjured up by Witch Doctors at the Federal Reserve to help ‘manage’ the Covidpocalypse.
Therefore, you’re also paying for Moderna’s antics and operations in the “health space” as a whole. When they buy a company for $85 million dollars (see the bottom of this article for a vomit-inducing trip down a DNA-company wormhole) — it’s done, in large part (if not nearly entirely?) with your money.
Start here:
Moderna — News
Go have a look for yourself.
Below you’ll find some absolutely mind-blowing stats and figures.
Published a short piece on the first find earlier (more info on that below) — but there are many more:
MODERNA ANNOUNCES MRNA-1345, AN INVESTIGATIONAL RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE, HAS MET PRIMARY EFFICACY ENDPOINTS IN PHASE 3 TRIAL IN OLDER ADULTS
mRNA-1345 demonstrated vaccine efficacy of 83.7% against RSV lower respiratory tract disease, defined by 2 or more symptoms in older adults
mRNA-1345 was generally well-tolerated, with no safety concerns identified by the DSMB
Based on these results, Moderna intends to submit mRNA-1345 for regulatory approval
CAMBRIDGE, MA, ACCESSWIRE / January 17, 2023 / Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced positive topline data from its ConquerRSV Phase 3 pivotal efficacy trial of mRNA-1345, an investigational mRNA vaccine targeting respiratory syncytial virus (RSV) in older adults. Following review by an independent Data and Safety Monitoring Board (DSMB), the primary efficacy endpoints have been met, including vaccine efficacy (VE) of 83.7% (95.88% CI: 66.1%, 92.2%; p<0.0001) against RSV-associated lower respiratory tract disease (RSV-LRTD) as defined by two or more symptoms. Based on these results, Moderna intends to submit for regulatory approval in the first half of 2023.
MODERNA ANNOUNCES ADVANCES ACROSS MRNA PIPELINE AND PROVIDES BUSINESS UPDATE
Read that closely.
2022: $18.4 Billion Dollars in Death-Cult Bad-JuJu Injections sales.
2022: $18,400,000,000 in Killer Kool-Aid Juice sales.
Who’s paying for it?
YOU ARE. Of course, with your tax dollars.
2023: $5.0 ADDITIONAL BILLION dollars in recurring Killer JuJu Mystery Injectables sales.
COVID-19 vaccine sales for 2022 approximately $18.4 billion (unaudited)
Reiterating 2023 expected minimum COVID-19 vaccine sales of approximately $5.0 billion; continue to expect additional contracts for 2023
Company continues to scale with 48 programs in development, including 36 in ongoing clinical studies, and is increasing R&D investment to an expected $4.5 billion for 2023
Pivotal Phase 3 RSV study of mRNA-1345 in older adults ( ≥ 60 yrs.) has now accrued the cases required to complete our first interim efficacy analysis
Moderna and Merck announced mRNA-4157/V940, in combination with KEYTRUDA, demonstrated a 44% reduction in the risk of disease recurrence or death in melanoma patients. Phase 3 study in melanoma patients to start in 2023, with rapid expansion to additional tumor types
Phase 1/2, multiple ascending dose Paramount study of propionic acidemia (PA) candidate (mRNA-3927) is ongoing
And here’s another.
CytomX recently cut 40% of its staff in July, 2022:
CytomX slashes headcount by 40% after breast cancer setback, with later-stage development bearing the brunt
Now that they’re running lean, Moderna to the rescue (with your tax dollars) — with a $35 million cash infusion (minimum — many of the post-deal parameters are likely incentive and performance based) and ongoing collaboration. Wonderful.
MODERNA AND CYTOMX ANNOUNCE STRATEGIC RESEARCH COLLABORATION FOR MRNA-BASED CONDITIONALLY ACTIVATED THERAPEUTICS
Collaboration will combine Moderna's mRNA technology with CytomX's Probody® Platform to generate and develop therapeutics for oncology and non-oncology conditions
CytomX to receive $35 million upfront payment with the potential for additional research, milestone, and royalty payments
But wait, there’s more!
MODERNA TO ACQUIRE ORICIRO GENOMICS
OriCiro's synthetic biology and enzyme technologies will support Moderna's expanding portfolio of therapeutics and vaccines
Acquisition will bolster Moderna's suite of platform technologies
CAMBRIDGE, MA and TOKYO, JAPAN / ACCESSWIRE / January 4, 2023 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and OriCiro Genomics K.K., a pioneer in cell-free DNA synthesis and amplification technologies, today announced they have entered into a definitive agreement through which Moderna will acquire OriCiro for $85 million.
"With this acquisition, we obtain best-in-class tools for cell-free synthesis and amplification of plasmid DNA, a key building block in mRNA manufacturing," said Stéphane Bancel, Chief Executive Officer of Moderna. "OriCiro's technology strategically complements our manufacturing expertise and further accelerates our research and development engine. We look forward to welcoming the OriCiro team to Moderna."
"Moderna has demonstrated remarkable speed and ability to impact lives through their innovative platform and mRNA therapeutics. I am confident that our technology and talent will be a highly strategic fit with Moderna," said Nasir Kato Bashiruddin, Chief Executive Officer of OriCiro.
"We are thrilled to join forces with Moderna to realize the full power of OriCiro for the benefit of patients," added Seiji Hirasaki, President and Co-founder of OriCiro.
I don’t know, nor do I claim to know what, exactly .. so-called “cell-free synthesis and amplification of plasmid DNA” is — but I sure as hell do not want it anywhere near my body.
And I definitely don’t want any sort of government mandate that it goes in my body either.
It’s probably best if you don’t ingest anything made by these toxic, snake oil peddling, thieving scumlords — no matter what they or the TV tell you.
If you do, I highly suggest regularly consuming Ivermectin and other far less harmful medicines to try to counteract the damage being done to your immune system, organs, and whatever else is being harmed.
🤮👹